A 104-week, randomized, double-blind, parallel group, multi-center Phase IIIb study comparing
the effects of treatment with rosuvastatin 40 mg or atorvastatin 80 mg on atherosclerotic
disease burden as measured by intravascular ultrasound in patients with coronary artery
disease.